Hypoactive delirium in the critical care setting

Kendra J. Schomer, Rachelle L. Firestone, Patricia L. Parker, Glen Xiong

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In hospitalized patients the rate of delirium can range from 19% to 82%, with the highest occurrence in the intensive care unit (ICU) population. In adult medical ICU patients, hypoactive delirium is substantially more common than hyperactive delirium (43.5% vs. 1.6%) and is frequently overlooked, leading to inadequate treatment and considerable risk for worse outcomes. National guidelines make no recommendation for the use of any specific pharmacologic agent for delirium prevention, therefore emphasis is placed on the choice of sedative and analysis of each sedative agent’s propensity to either cause or exacerbate delirium. Robust evidence for pharmacologic treatment of hypoactive delirium is currently lacking. Resolution of the underlying cause or causes of delirium remains at the forefront of treatment. Considering the clinical and financial consequences of delirium in the ICU, studies to further characterize and investigate the prevention and treatment of hypoactive delirium are needed to guide management. This chapter will focus largely on preventative strategies as well as some considerations for treatment of hypoactive delirium.

Original languageEnglish (US)
Title of host publicationDelirium
Subtitle of host publicationPrevention, Symptoms and Treatment
PublisherNova Science Publishers, Inc.
Pages93-101
Number of pages9
ISBN (Electronic)9781536123876
ISBN (Print)9781536123852
StatePublished - Jan 1 2017

Fingerprint

Delirium
Critical Care
Intensive Care Units
Hypnotics and Sedatives
Therapeutics
Guidelines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schomer, K. J., Firestone, R. L., Parker, P. L., & Xiong, G. (2017). Hypoactive delirium in the critical care setting. In Delirium: Prevention, Symptoms and Treatment (pp. 93-101). Nova Science Publishers, Inc..

Hypoactive delirium in the critical care setting. / Schomer, Kendra J.; Firestone, Rachelle L.; Parker, Patricia L.; Xiong, Glen.

Delirium: Prevention, Symptoms and Treatment. Nova Science Publishers, Inc., 2017. p. 93-101.

Research output: Chapter in Book/Report/Conference proceedingChapter

Schomer, KJ, Firestone, RL, Parker, PL & Xiong, G 2017, Hypoactive delirium in the critical care setting. in Delirium: Prevention, Symptoms and Treatment. Nova Science Publishers, Inc., pp. 93-101.
Schomer KJ, Firestone RL, Parker PL, Xiong G. Hypoactive delirium in the critical care setting. In Delirium: Prevention, Symptoms and Treatment. Nova Science Publishers, Inc. 2017. p. 93-101
Schomer, Kendra J. ; Firestone, Rachelle L. ; Parker, Patricia L. ; Xiong, Glen. / Hypoactive delirium in the critical care setting. Delirium: Prevention, Symptoms and Treatment. Nova Science Publishers, Inc., 2017. pp. 93-101
@inbook{869d618e30ef42a594585f4c57b088e6,
title = "Hypoactive delirium in the critical care setting",
abstract = "In hospitalized patients the rate of delirium can range from 19{\%} to 82{\%}, with the highest occurrence in the intensive care unit (ICU) population. In adult medical ICU patients, hypoactive delirium is substantially more common than hyperactive delirium (43.5{\%} vs. 1.6{\%}) and is frequently overlooked, leading to inadequate treatment and considerable risk for worse outcomes. National guidelines make no recommendation for the use of any specific pharmacologic agent for delirium prevention, therefore emphasis is placed on the choice of sedative and analysis of each sedative agent’s propensity to either cause or exacerbate delirium. Robust evidence for pharmacologic treatment of hypoactive delirium is currently lacking. Resolution of the underlying cause or causes of delirium remains at the forefront of treatment. Considering the clinical and financial consequences of delirium in the ICU, studies to further characterize and investigate the prevention and treatment of hypoactive delirium are needed to guide management. This chapter will focus largely on preventative strategies as well as some considerations for treatment of hypoactive delirium.",
author = "Schomer, {Kendra J.} and Firestone, {Rachelle L.} and Parker, {Patricia L.} and Glen Xiong",
year = "2017",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781536123852",
pages = "93--101",
booktitle = "Delirium",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Hypoactive delirium in the critical care setting

AU - Schomer, Kendra J.

AU - Firestone, Rachelle L.

AU - Parker, Patricia L.

AU - Xiong, Glen

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In hospitalized patients the rate of delirium can range from 19% to 82%, with the highest occurrence in the intensive care unit (ICU) population. In adult medical ICU patients, hypoactive delirium is substantially more common than hyperactive delirium (43.5% vs. 1.6%) and is frequently overlooked, leading to inadequate treatment and considerable risk for worse outcomes. National guidelines make no recommendation for the use of any specific pharmacologic agent for delirium prevention, therefore emphasis is placed on the choice of sedative and analysis of each sedative agent’s propensity to either cause or exacerbate delirium. Robust evidence for pharmacologic treatment of hypoactive delirium is currently lacking. Resolution of the underlying cause or causes of delirium remains at the forefront of treatment. Considering the clinical and financial consequences of delirium in the ICU, studies to further characterize and investigate the prevention and treatment of hypoactive delirium are needed to guide management. This chapter will focus largely on preventative strategies as well as some considerations for treatment of hypoactive delirium.

AB - In hospitalized patients the rate of delirium can range from 19% to 82%, with the highest occurrence in the intensive care unit (ICU) population. In adult medical ICU patients, hypoactive delirium is substantially more common than hyperactive delirium (43.5% vs. 1.6%) and is frequently overlooked, leading to inadequate treatment and considerable risk for worse outcomes. National guidelines make no recommendation for the use of any specific pharmacologic agent for delirium prevention, therefore emphasis is placed on the choice of sedative and analysis of each sedative agent’s propensity to either cause or exacerbate delirium. Robust evidence for pharmacologic treatment of hypoactive delirium is currently lacking. Resolution of the underlying cause or causes of delirium remains at the forefront of treatment. Considering the clinical and financial consequences of delirium in the ICU, studies to further characterize and investigate the prevention and treatment of hypoactive delirium are needed to guide management. This chapter will focus largely on preventative strategies as well as some considerations for treatment of hypoactive delirium.

UR - http://www.scopus.com/inward/record.url?scp=85034980757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034980757&partnerID=8YFLogxK

M3 - Chapter

SN - 9781536123852

SP - 93

EP - 101

BT - Delirium

PB - Nova Science Publishers, Inc.

ER -